Mitochondrial Dysfunction and Coenzyme Q10 Supplementation in Post-Viral Fatigue Syndrome: An Overview

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(1), P. 574 - 574

Published: Jan. 1, 2024

Post-viral fatigue syndrome (PVFS) encompasses a wide range of complex neuroimmune disorders unknown causes characterised by disabling post-exertional fatigue, myalgia and joint pain, cognitive impairments, unrefreshing sleep, autonomic dysfunction, neuropsychiatric symptoms. It includes myalgic encephalomyelitis, also known as chronic (ME/CFS); fibromyalgia (FM); more recently post-COVID-19 condition (long COVID). To date, there are no definitive clinical case criteria FDA-approved pharmacological therapies for PVFS. Given the current lack effective treatments, is need to develop novel therapeutic strategies these disorders. Mitochondria, cellular organelles responsible tissue energy production, have garnered attention in research into PVFS due their crucial role bioenergetic metabolism conditions. The accumulating literature has identified link between mitochondrial dysfunction low-grade systemic inflammation ME/CFS, FM, long COVID. address this issue, article aims critically review evidence relating pathogenesis disorders; particular, it evaluate effectiveness coenzyme Q10 supplementation on pain symptoms strategy treatment

Language: Английский

---

The Course of COVID-19 and Long COVID: Identifying Risk Factors among Patients Suffering from the Disease before and during the Omicron-Dominant Period

Pathogens, Journal Year: 2024, Volume and Issue: 13(3), P. 267 - 267

Published: March 20, 2024

SARS-CoV-2 has acquired many mutations that influence the severity of COVID-19's course or risk developing long COVID. In 2022, dominant variant was Omicron. This study aimed to compare COVID-19 in periods before and during dominance Omicron variant. Risk factors for COVID were also assessed. based on stationary visits patients after follow-up assessments 3 months. Clinical symptoms, comorbidities, vaccination status evaluated 1967 patients. Of analyzed group, 1308 (66.5%) affected by period dominance. The prevalence significantly lower among group (47.7% vs. 66.9%,

Language: Английский

---

Incidence, severity, risk factors and outcomes of SARS-CoV-2 reinfections during the Omicron period: a systematic review and meta-analysis

Journal of Global Health, Journal Year: 2025, Volume and Issue: 15

Published: Feb. 7, 2025

Abstract Background Our previous systematic review estimated the cumulative incidence of SARS-CoV-2 reinfections as 1.16% (95% CI = 1.01–1.33%) during pre-Omicron period. The Omicron variant that emerged in November 2021 was significantly genetically distinct from variants and thus, more transmissible posed an increased risk population. We, therefore, conducted a fresh meta-analysis to estimate reinfection burden Methods We searched CINAHL, Medline, Global Health, Embase, WHO COVID-19 October 2023 for studies reporting quality included assessed using Joanna Briggs Institute checklists. Random effects meta-analyses were incidence, requirement hospitalisation reinfections. Symptomatic severity case fatality rates analysed narratively. Results Thirty-six included. period 3.35% 1.95–5.72%) based on data 28 studies. higher 18–59-year-old adults (6.62% 3.22–13.12%)) compared other age groups health care workers (9.88% 5.18–18.03%)) general population (2.48% 1.34–4.54%)). about 1.81% 0.18–15.87%) reinfected cases required limited highly variable data. Conclusions There generally less severe However, disease long-term outcomes. Registration PROSPERO: CRD42023482598.

Language: Английский

---

Early COVID-19 and protection from Omicron in a highly vaccinated population in Ontario, Canada: a matched prospective cohort study

BMC Infectious Diseases, Journal Year: 2025, Volume and Issue: 25(1)

Published: Feb. 8, 2025

Abstract Objectives Predictions regarding the on-going burden of SARS-CoV-2, and vaccine recommendations, require an understanding infection-associated immune protection. We assessed whether early COVID-19 provided protection against Omicron infection. Methods enrolled a cohort adults in Ontario, Canada, with prior to October 2020 (early infection, EI), matched testing negative PCR (non-EI). Participants completed baseline surveys then every two weeks until January 2023. Multivariable Cox regression was used assess factors associated infection during first 14 months Omicron. Results Overall, 624 EI (70%) 175 (77%) non-EI participants met criteria for analysis; 590 (95%) 164 (94%) had received at least 2 doses Of EI, (28%) one SARS-CoV-2 re-infection 8 (1.3%) two, compared 84 (48%) one, 5 (2.9%) 1 (0.6%) 3 infections ( P < 0.0001). In multivariable analysis risk overall hazard ratio (HR, 95%CI) 0.56 (0.43–0.74); HRs BA.1/2, BA.4/5 mixed BA.5/BQ.1/XBB periods were 0.66 (0.45–0.97), 0.44 (0.28–0.68) 0.71 (0.32–1.56). BA.1/2 combined reduced later (HR 0.07 (0.03–0.21) no Older age, non-White ethnicity, children household, lower neighbourhood income Conclusions our highly vaccinated population, 44% reduction symptomatic Omicron, providing significant more than years.

Language: Английский

---

Assessment of the factors affecting the clinical outcomes of infection and safety of vaccines against SARS-CoV-2 among Egyptian patients

BMC Infectious Diseases, Journal Year: 2025, Volume and Issue: 25(1)

Published: March 19, 2025

Abstract Background Understanding the factors that influence clinical outcomes of COVID-19 and safety various vaccines is important to inform public health strategies, particularly in diverse communities. This study aimed assess affecting vaccination among Egyptian population. Methods In a retrospective study, we examined 1597 patients who tested positive for COVID-19. Among them, 1280 had received vaccination, while 317 not. We collected data from medical records, which included characteristics, comorbidities, disease severity, type adverse hematological effects postvaccination. calculated relative risk, odds ratio, 95% confidence intervals (CIs). Results 1,597 cases, 74.1% were mild, 24.8% moderate, 1.1% severe. Significant moderate/severe cases male sex (RR 0.78, CI 0.64–0.95), cardiovascular diseases 1.86, 1.32–2.64), respiratory 1.40, 1.08–1.82), diabetes mellitus 1.41, 1.07–1.86), previous infection 1.22, 1.02–1.46). Vaccination reduced severity with BBIBP-CorV (Sinopharm) showing significant protective effect (OR 0.62–0.98). Clinical presentations varied, 97.6% having an oxygen saturation ≥ 92%. Logistic regression indicated factors. Linear revealed increased hemoglobin leucocyte counts, whereas decreased platelet counts. Conclusion Vaccination, (Sinopharm), significantly reduces Egyptians, despite effects. trial number Not applicable.

Language: Английский

---

Clinical characteristics, SARS-CoV-2 variants, and outcomes of adults hospitalized due to COVID-19 in Latin American countries

Clinics, Journal Year: 2025, Volume and Issue: 80, P. 100648 - 100648

Published: Jan. 1, 2025

Language: Английский

---

Natural, vaccine-induced immunity and the probability of experiencing SARS-CoV-2 infection in a household cohort in Rio de Janeiro

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: May 17, 2025

The impact of COVID-19 vaccines on real-world transmission remains poorly understood and represents a key public health challenge. This study aimed to investigate natural, vaccine-induced immunity the probability experiencing SARS-CoV-2 infection in cohort families living Rio de Janeiro. participants were categorized into immune groups based recent (within past 9 months) vaccination status, considering type vaccine received, number doses, strength their response over time. We estimated within clusters using multivariate model. From May 2020 June 2023, we enrolled 669 individuals from 182 households; 272 288 index cases identified. Household occurred 124 (45.6%) clusters. During pre-VoC period did not find any factors associated with transmission. In Gamma/Delta period, previous infections reduced (OR = 0.088; 95%CI 0.023-0.341), while Omicron having healthcare worker household 0.486; 0.256-0.921) hybrid 0.095; 0.010-0.924) decreased Our findings provide strong support for protective effect regular against exposed successive variants.

Language: Английский

---

Longitudinal Analysis of Humoral and Cellular Immune Response up to 6 Months after SARS-CoV-2 BA.5/BF.7/XBB Breakthrough Infection and BA.5/BF.7-XBB Reinfection

Vaccines, Journal Year: 2024, Volume and Issue: 12(5), P. 464 - 464

Published: April 26, 2024

The rapid mutation of SARS-CoV-2 has led to multiple rounds large-scale breakthrough infection and reinfection worldwide. However, the dynamic changes humoral cellular immunity responses several subvariants after remain unclear. In our study, a 6-month longitudinal immune response evaluation was conducted on 118 sera 50 PBMC samples from 49 healthy individuals who experienced BA.5/BF.7/XBB or BA.5/BF.7-XBB reinfection. By studying antibody response, memory B cell, IFN-γ secreting CD4+/CD8+ T cell variants, we observed that each component exhibited distinct kinetics. Either induces relatively high level binding neutralizing titers against Omicron at an early time point, which rapidly decreases over time. Most 6 months post-breakthrough completely lost their activities BQ.1.1, CH.1.1, BA.2.86, JN.1 XBB subvariants. Individuals with exhibit imprinting shifting recall pre-existing BA.5/BF.7 neutralization antibodies. BA.5 group, frequency XBB.1.16-RBD specific cells, resting intermediate cells gradually increased On other hand, induced by WT/BA.5/XBB.1.16 spike trimer remains stable Overall, research indicates have declining levels but can provide some degree protection future exposure new antigens.

Language: Английский

---

Clinical features and outcomes in adults with COVID-19 during the pre-Omicron and Omicron waves

Infectious Diseases Now, Journal Year: 2023, Volume and Issue: 54(2), P. 104833 - 104833

Published: Nov. 15, 2023

Language: Английский

---

Prognosis of patients with long COVID symptoms: a protocol for a longitudinal cohort study at a primary care referred outpatient clinic in Helsinki, Finland

BMJ Open, Journal Year: 2023, Volume and Issue: 13(10), P. e072935 - e072935

Published: Oct. 1, 2023

Introduction After COVID-19, many continue to experience persistent debilitating symptoms, that is, long COVID. Its most prevalent symptoms are chest pain, difficulties with breathing, painful muscles, ageusia or anosmia, tingling extremities and general tiredness. This paper describes the protocol of Long COVID Cohort Study assess prognosis prognostic determinants patients by implementing patient-reported outcome measures (PROMs), (PREMs) clinical examinations during a 1-year follow-up. Methods analysis is prospective, single-site cohort study consisting administering questionnaires adult referred Clinic for Long-Term Effects COVID-19 at Helsinki University Hospital (Hospital district Uusimaa). The referrals from all healthcare units within HUS other hospital districts years 2021–2023. All admitted have had laboratory-confirmed COVID-19. targeted sample size 500 participants. administered 0, 3, 6 12 months. main variables changes in self-reported functional abilities quality life. In addition, we will evaluate baseline using neurocognitive evaluation, 6MWT measurement hand grip strength. form register clinic characterise first systematic collection PROMs, PREMs, questionnaire related Finland. belongs consortium COVID—HORIZON-HLTH-2021-DISEASE-04 aims reveal biomechanisms Ethics dissemination has been approved research ethics committee board, ID HUS/1493/2021 on March 2021. participants sign written informed consent participation. findings be reported publication peer-reviewed journals. Trial registration number NCT05699512; Pre-results .

Language: Английский

---